NASDAQ:TXMD - TherapeuticsMD Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding TherapeuticsMD Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.42 -0.01 (-0.41 %) (As of 12/9/2019 04:00 PM ET) Add Compare Today's Range$2.34Now: $2.42▼$2.4650-Day Range$2.36MA: $2.75▼$3.7952-Week Range$1.82Now: $2.42▼$6.09Volume2.29 million shsAverage Volume3.27 million shsMarket Capitalization$656.25 millionP/E RatioN/ADividend YieldN/ABeta1.66 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TXMD Previous SymbolNYSEMKT:TXMD CUSIPN/A CIK25743 Webhttp://www.therapeuticsmd.com/ Phone561-961-1900Debt Debt-to-Equity Ratio24.29 Current Ratio2.85 Quick Ratio2.69Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$16.10 million Price / Sales40.76 Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book5.90Profitability EPS (Most Recent Fiscal Year)($0.59) Net Income$-132,620,000.00 Net Margins-427.70% Return on Equity-430.28% Return on Assets-70.11%Miscellaneous Employees241 Outstanding Shares271,177,000Market Cap$656.25 million Next Earnings Date2/20/2020 (Estimated) OptionableOptionable Receive TXMD News and Ratings via Email Sign-up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:TXMD Rates by TradingView TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions What is TherapeuticsMD's stock symbol? TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD." How were TherapeuticsMD's earnings last quarter? TherapeuticsMD Inc (NASDAQ:TXMD) issued its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.19) by $0.06. The company had revenue of $8.21 million for the quarter, compared to analyst estimates of $8.05 million. TherapeuticsMD had a negative net margin of 427.70% and a negative return on equity of 430.28%. The business's revenue for the quarter was up 136.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.16) earnings per share. View TherapeuticsMD's Earnings History. When is TherapeuticsMD's next earnings date? TherapeuticsMD is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for TherapeuticsMD. What guidance has TherapeuticsMD issued on next quarter's earnings? TherapeuticsMD updated its FY 2019 earnings guidance on Wednesday, October, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $29.45-34.2 million, compared to the consensus revenue estimate of $31.45 million. What price target have analysts set for TXMD? 9 brokerages have issued 12-month price targets for TherapeuticsMD's stock. Their forecasts range from $3.00 to $17.00. On average, they anticipate TherapeuticsMD's share price to reach $9.11 in the next year. This suggests a possible upside of 276.5% from the stock's current price. View Analyst Price Targets for TherapeuticsMD. What is the consensus analysts' recommendation for TherapeuticsMD? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TherapeuticsMD. What are Wall Street analysts saying about TherapeuticsMD stock? Here are some recent quotes from research analysts about TherapeuticsMD stock: 1. According to Zacks Investment Research, "TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. " (10/19/2019) 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating. The execution behind the launches of Annovera is underappreciated, in our view, and we think peak sales could exceed modest expectations for three drugs that target large unmet needs. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our 12-month PT of $27. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of EV/EBITDA and DCF analysis to arrive at our 12-month PT of $27." (1/21/2019) Has TherapeuticsMD been receiving favorable news coverage? News articles about TXMD stock have been trending somewhat positive recently, InfoTrie reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. TherapeuticsMD earned a daily sentiment score of 1.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for TherapeuticsMD. Who are some of TherapeuticsMD's key competitors? Some companies that are related to TherapeuticsMD include Amicus Therapeutics (FOLD), Zai Lab (ZLAB), Agios Pharmaceuticals (AGIO), Arena Pharmaceuticals (ARNA), Ultragenyx Pharmaceutical (RARE), Xencor (XNCR), Heron Therapeutics (HRTX), Portola Pharmaceuticals (PTLA), Eidos Therapeutics (EIDX), Ra Pharmaceuticals (RARX), Zogenix (ZGNX), Tricida (TCDA), Insmed (INSM), Cambrex (CBM) and Ironwood Pharmaceuticals (IRWD). What other stocks do shareholders of TherapeuticsMD own? Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include Opko Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), CannTrust (CNTTF), Cleveland-Cliffs (CLF), NVIDIA (NVDA), Horizon Therapeutics (HZNP), bluebird bio (BLUE), Synergy Pharmaceuticals (SGYP) and Micron Technology (MU). Who are TherapeuticsMD's key executives? TherapeuticsMD's management team includes the folowing people: Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 48)Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 57)Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 51)Mr. Daniel Alan Cartwright, CFO & Treasurer (Age 61)Mr. Mitchell L. Krassan, Exec. VP & Chief Strategy Officer (Age 53) Who are TherapeuticsMD's major shareholders? TherapeuticsMD's stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (1.74%), Stifel Financial Corp (1.00%), Rice Hall James & Associates LLC (0.24%), Bay Colony Advisory Group Inc d b a Bay Colony Advisors (0.22%), SG Americas Securities LLC (0.13%) and 1492 Capital Management LLC (0.13%). Company insiders that own TherapeuticsMD stock include Angus C Russell, Brian Bernick, Daniel A Cartwright, Group L P Column, Jane F Barlow, John CK Iv Milligan, Jules A Musing, Robert G Finizio and Tommy G Thompson. View Institutional Ownership Trends for TherapeuticsMD. Which institutional investors are selling TherapeuticsMD stock? TXMD stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Voya Investment Management LLC, 1492 Capital Management LLC, Millennium Management LLC, State Street Corp, Oppenheimer & Co. Inc. and Great West Life Assurance Co. Can. Company insiders that have sold TherapeuticsMD company stock in the last year include Brian Bernick, John CK Iv Milligan, Jules A Musing and Robert G Finizio. View Insider Buying and Selling for TherapeuticsMD. Which institutional investors are buying TherapeuticsMD stock? TXMD stock was bought by a variety of institutional investors in the last quarter, including Bay Colony Advisory Group Inc d b a Bay Colony Advisors, Barclays PLC, Squarepoint Ops LLC, California Public Employees Retirement System, Commonwealth Equity Services LLC, Nisa Investment Advisors LLC, Moors & Cabot Inc. and Rice Hall James & Associates LLC. Company insiders that have bought TherapeuticsMD stock in the last two years include Angus C Russell, Brian Bernick, Group L P Column, Jane F Barlow, John CK Iv Milligan, Robert G Finizio and Tommy G Thompson. View Insider Buying and Selling for TherapeuticsMD. How do I buy shares of TherapeuticsMD? Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is TherapeuticsMD's stock price today? One share of TXMD stock can currently be purchased for approximately $2.42. How big of a company is TherapeuticsMD? TherapeuticsMD has a market capitalization of $656.25 million and generates $16.10 million in revenue each year. The company earns $-132,620,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. TherapeuticsMD employs 241 workers across the globe.View Additional Information About TherapeuticsMD. What is TherapeuticsMD's official website? The official website for TherapeuticsMD is http://www.therapeuticsmd.com/. How can I contact TherapeuticsMD? TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The company can be reached via phone at 561-961-1900 or via email at [email protected] MarketBeat Community Rating for TherapeuticsMD (NASDAQ TXMD)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 327 (Vote Outperform)Underperform Votes: 281 (Vote Underperform)Total Votes: 608MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/9/2019 by MarketBeat.com StaffFeatured Article: Are we seeing the beginning of a new bubble?
